Storys zum Thema Medikament

DHL Group

4

PM: DHL liefert die erste mobile Herzklinik nach Burundi / PR: DHL delivers the world's first mobile heart clinic to Burundi

PNO Innovation GmbH

SGLT2 HYPE: New EU-funded Project Aims to Transform Hypertension Treatment

Ottobock SE & Co. KGaA

Ottobock invests in innovative technologies from MIT Start-ups

STADA Arzneimittel AG

3

Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...

CO.DON GmbH

CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration

Teltow (ots) - The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform. m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, ...

Norgine GmbH

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...

Helmholtz Munich

Ancient Viral DNA Shapes Early Embryo Development

Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the "dark side" of the genome, researchers at Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have now revealed their crucial role in early embryo development. Unanswered Questions About the Role of Ancient Viral DNA Transposable ...

Asklepios Kliniken GmbH & Co. KGaA

Nomination period for the Broermann Medical Innovation Award started

Gießen (ots) - - Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine - Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is ...

LTS Lohmann Therapie-Systeme AG

LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships

Helmholtz Munich

SCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues

Grünenthal Group

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Norgine GmbH

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...

RHEACELL GmbH und Co. KG

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Gerresheimer AG

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

Helmholtz Munich

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Technische Universität München

New method for designing artificial proteins

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Designing large new proteins with AI New method for designing artificial proteins - Efficient design of new proteins with desired properties - Size of newly designed proteins is approaching that of antibodies - Predicted protein structures successfully validated in experiments Protein design aims to create customized antibodies for therapies, biosensors for diagnostics, or ...

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

Ottobock SE & Co. KGaA

Ottobock invests in NeuroTech company ONWARD® Medical

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

PNO Innovation GmbH

Event Announcement: VIROFIGHT Hybrid Symposium

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...